CUL4A (Cullin 4A)

These findings reveal a Cul4A-WDR5-dependent proteolysis pathway regulating HR protein stability via phosphatidyl inositol signaling. This mechanism offers a promising therapeutic strategy for overcoming PARPi resistance and improving combinatorial cancer treatment strategies.

We also noted contrasts in nucleotide-excision-repair involvement (ERCC5/POLE mutations vs ERCC1/CUL4A CNV gains), and mutational-signature analysis indicated greater MMR- and AID/POLE-associated exposures in the White cohort. To our knowledge, this study provides an initial multi-omics characterization of breast tumors from Native American women and offers a resource and hypotheses for larger, harmonized studies to assess prognostic and therapeutic relevance.

In addition, ectopic expression of KMD5D in a cisplatin‑resistant cell line reversed these phenomena. The results suggest that KDM5D and/or CUL4A may be a biomarkers of chemoresistance to cisplatin and a potential therapeutic target in neuroblastoma.

Thus, we define a novel N-degron pathway that monitors replacement of myristoylation by acetylation and activates degradation of SFKs upon acetylation. This mechanism may extend to other N-terminally myristoylated proteins beyond SFKs.

We evaluated 5 recently established brain aging indices, which capture the heterogeneity of structural brain aging, in ADSP participants. R-indices replicated previously reported associations with AD groups (Yang et al., 2024), indicating the generalizability of the model. We identified different associations with genes that were previously linked to various traits. These findings provide new insights into the exploration of heterogeneity of neurodegeneration and related genetic risk factors.

The CSC-defective traits in DDB1-deficient CRC cells were rescued by p53 deficiency but not by its overexpression, indicating that the CUL4A-DDB1-mediated regulation of p53 stability may control cancer stem-like properties in CRC. In summary, our findings emphasize DDB1 as a key regulator of colorectal cancer stemness and p53 stability through its O-GlcNAcylation at Ser-764, which enhances the E3 ligase activity of the CUL4-DDB1 complex.

Mechanistically, TPM3-TRKA degradation by compound 9 was dependent on CRBN-mediated polyubiquitination and proteasomal degradation; accordingly, it was hindered by inhibitors of the proteasome (MG132) or Cullins (MLN4924), by dominant negative Cullin 4A mutant, and by free pomalidomide. Finally, a compound 9 derivative, compound 20, induced in vivo degradation of TMP3-TRKA in KM12 cells mouse xenografts. In conclusion, our study indicated that PROTAC-mediated degradation is an efficient strategy to intercept RET and TRKA oncogenic signaling.

Herein, we designed, synthesized and evaluated bromodomain 4 (BRD4)-targeting PROTACs (BRD4-PROTACs) that employ a well-known BRD4 inhibitor (JQ1) as a warhead and Vpr-derived peptides as the E3 ligase-binding ligands...The chemical degraders are less effective than the parent inhibitor as a latency-reversing agent (LRA). However, the low cytotoxicity of the new peptidic PROTACs allowed the compounds to be tolerated at high does, leading to potent LRA activity.

Furthermore, KAT2A enhances the transcription of the MAGE-A10 gene, forming a positive feedback loop that contributes to tumorigenesis. These findings provide insights into the molecular mechanisms hijacked in cancer that drive perturbed histone acetylation and suggest potential therapeutic strategies.

Among these, CUL4A and YWHAH enhanced sE1E2 secretion in our glycoengineered CHO cells. The integration of omics techniques and genetic engineering in this study provides valuable insights into the host cell proteins that interact with the HCV E1E2 heterodimer, and how they may be harnessed to improve protein secretion in CHO cells to enable more affordable and accessible biotherapeutics.

Notably, their susceptibility to spontaneous, radiation-, and chemically induced malignancies was significantly higher. These findings support the role of AMBRA1 as a tumor suppressor that regulates cyclin Ds, although other targets may also contribute.

This study provides novel insight into the role of cullin genes in READ, suggesting that CUL2 and CUL7 may be biomarkers and therapeutic targets. Further research is warranted to explore their underlying mechanisms and clinical applications in READ management.